Vertex announced its drug VX-770 for cystic fibrosis (CF) had done well in another phase III trial with 52 patients. The drug targets CF patients with a specific genetic defect that represents about 4% of the total CF population. VX-770 improved these patients lung function by a significant 12.5 percent. Vertex says the drug remains on track for an anticipated FDA filing in late 2011.
"We are committed to making VX-770 available as soon as possible and are moving ahead quickly with our US and European applications for regulatory approval...", said Robert Kaufman, the CMO at Vertex. Vertex stock increased by 2.2 percent on the news of the positive trial result. See Fierce Biotech.
Posted by Bruce Lehr March 29th 2011.
Comments